Sareum (LON:SAR) Posts Earnings Results

Sareum (LON:SAR) announced its quarterly earnings data on Thursday. The company reported GBX (2.40) earnings per share for the quarter, Digital Look Earnings reports.

Sareum Stock Performance

Shares of SAR stock opened at GBX 15 on Friday. The stock has a market capitalization of £20.71 million, a P/E ratio of -5.77 and a beta of -1.08. The company has a 50 day moving average price of GBX 21.99 and a 200 day moving average price of GBX 18.50. Sareum has a fifty-two week low of GBX 9.50 and a fifty-two week high of GBX 29.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.